Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout Nature 629 , 1011-1012 (2024) doi: References Petersen, J
Mutation update and review of severe methylenetetrahydrofolate reductase deficiency
Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells
6 Since then, states have altered their positions on covering anti-obesity GLP-1 therapies: Four have withdrawn coverage entirely (California, New Hampshire, Pennsylvania, and South Carolina), three have added coverage (Missouri, Tennessee, and Utah), and at least two states (Michigan and Virginia) have enacted more narrow utilization criteria, limiting future use to those with morbid obesity
